Factors associated with melanoma incidence and prognosis

Seminars in Surgical Oncology

Volumn 12, Issue 6, 1996, Pages 379-385

  Lee, Jeffrey E ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

melanoma etiology incidence diagnosis genetics immunology; neoplasm metastasis; prognosis; risk factors

Indexed keywords

HLA ANTIGEN; TUMOR MARKER;

CANCER INCIDENCE; CANCER RISK; CANCER STAGING; CELL ONCOGENE; GENETIC RISK; HLA TYPING; HUMAN; MELANOMA; PRIORITY JOURNAL; PROGNOSIS; RACE DIFFERENCE; REVIEW; SKIN CARCINOGENESIS; SKIN COLOR; SUNLIGHT; TUMOR SUPPRESSOR GENE;

ADULT; AGE FACTORS; AGED; BIOLOGICAL MARKERS; FEMALE; GENES, TUMOR SUPPRESSOR; GENETIC MARKERS; HUMANS; MALE; MELANOMA; MUTATION; NEOPLASM METASTASIS; ONCOGENES; PROGNOSIS; RISK FACTORS; SEX FACTORS; SUNLIGHT; TUMOR MARKERS, BIOLOGICAL;

EID: 0029801958     PISSN: 87560437     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2388(199611/12)12:6<379::AID-SSU2>3.0.CO;2-7     Document Type: Review

References (50)

1. Lee JE: Melanoma. In Berger DH, Feig BW, Fuhrman GM (eds): "The M. D. Anderson Surgical Oncology Handbook." Boston: Little, Brown, 1996, 38-60.
2. Kirkwood JM, Strawderman MH, Ernstoff MS, et al: Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group trial EST 1684. J Clin Oncol 14:7-17, 1996.
3. Ariyan S, Poo WJ, Bolognia J, et al: Multiple primary melanomas: data and significance. Plast Reconstr Surg, 96:1384-1389, 1994.
4. Holly EA, Aston DA, Cress RD, et al: Cutaneous melanoma in women. II. Phenotypic characteristics and other host-related factors. Am J Epidemiol, 141:934-942, 1995.
5. Elwood JM: Melanoma and sun exposure: contrasts between intermittent and chronic exposure. World J Surg, 16:157-165, 1992.
6. Autier P, Dore JF, Lejeune F, et al: Cutaneous malignant and exposure to sunlamps or sunbeds: an EORTC multicenter case-control study in Belgium, France and Germany. Int J Cancer, 58:809-813, 1994.
7. Armstrong BK: Epidemiology of malignant melanoma: intermittent or total accumulated exposure to the sun? J Dermatol Surg Oncol 14:835-849, 1988.
8. Ceballos PI, Ruiz-Maldonado R, Mihm MC Jr. Melanoma in children. N Eng J Med, 332:656-662, 1995.
9. Slade J, Marghoob AA, Salopek TG, et al: Atypical mole syndrome: risk factor for cutaneous malignant melanoma and implications for management. J Am Acad Dermatol 32:479-494, 1995.
10. Riou JP, Ariyan S, Brandow KR, Fielding LP: The association between melanoma, lymphoma, and other primary neoplasms. Arch Surg 130:1056-1061, 1995.
11. American Joint Committee on Cancer. Manual for Staging of Cancer. 4th ed. Philadelphia: Lippincott, 1992, 143-148.
12. Balch CM, Cascinelli N, Drzewiecki KT, et al: A comparison of prognostic factors worldwide. In Balch CM, Houghton AN, Milton GW. et al. (eds): "Cutaneous Melanoma." 2nd ed. Philadelphia: Lippincott, 1992, 188-199.
13. Morton DL, Davtyan DG, Wanek LA, et al: Multivariate analysis of the relationship between survival and the microstage of primary melanoma by Clark level and Breslow thickness. Cancer 71: 3737-3743, 1993.
14. Park KG, Blessing K, McLaren KM, Watson AC: A study of thin (<1.5 mm) malignant melanomas with poor prognosis. Br J Plast Surg 46:607-610, 1993.
15. Austin PF, Cruse CW, Lyman G, et al: Age as a prognostic factor in the malignant melanoma population. Ann Surg Oncol, 1:487-494, 1994.
16. Veronesi U, Cascinelli N, Adamus J. et al: Thin stage I primary cutaneous melanoma. Comparison of excision with margins of 1 or 3 cm. N Engl J Med 318:1159-1173, 1988. [Published errata appears in N Engl J Med 325:292, 1991.]
17. Balch CM, Urist MM, Karakousis CP, et al: Efficacy of 2-cm surgical margins for intermediate-thickness melanomas ( 1 to 4 mm). Results of a multi-institutional randomized surgical trial. Ann Surg 218:262-269, 1993.
18. Ross MI, Reintgen D. Balch CM: Selective lymphadenectomy: emerging role for lymphatic mapping and sentinel node biopsy in the management of early stage melanoma. Semin Surg Oncol 9:219-223, 1993.
19. Balch CM: The role of elective lymph node dissection in melanoma: rationale, results and controversies. J Clin Oncol 6:163-172, 1988.
20. Balch CM, Buzaid AC: Finally, a successful adjuvant therapy for high-risk melanoma. J Clin Oncol 14:1-3, 1996.
21. Slingluff, CL Jr, Dodge RK, Stanley WE, Seigler HF: The annual risk of melanoma progression. Cancer 70:1917-1927, 1992.
22. Calabro A, Singletary SE. Balch CM. Patterns of relapse in 1001 consecutive patients with melanoma nodal metastases. Arch Surg 124:1051-1055, 1989.
23. Buzaid AC, Tinoco LA, Jendiroba D, Tu ZN, et al: Prognostic value of size of lymph node metastases in patients with cutaneous melanoma. J Clin Oncol 13:2361-2368, 1995.
24. Cascinelli N, Bufalino R, Marolda R, et al: Regional non-nodal metastases of cutaneous melanoma. Eur J Surg Oncol 12:175-180, 1986.
25. Barth A, Wanek LA, Morton DL: Prognostic factors in 1,521 melanoma patients with distant metastases. J Am Coll Surg, 181: 193-201, 1995.
26. Balch CM, Soong, SJ, Shaw HM, et al: An analysis of prognostic factors in 8500 patients with cutaneous melanoma. In Balch CM, Houghton AN, Milton GW, et al (eds): "Cutaneous Melanoma." 2nd ed. Philadelphia: Lippincott, 1992, 165-187.
27. Sirott MN, Bajorin DF, Wong GY, et al: Prognostic factors in patients with metastatic malignant melanoma. A multivariate analysis. Cancer, 72:3091-3098, 1993.
28. Trent JM: Cytogenetics of human malignant melanoma. In Balch CM, Houghton AN, Milton GW, et al (eds): "Cutaneous Melanoma." 2nd ed. Philadelphia: Lippincott, 1992, 101-111.
29. Cannon-Albright LA, Goldgar DE, Meyer LJ, et al: Assignment of a locus for familial melanoma, MLM. to chromosome 9p 13-p22. Science 258:1148-1152, 1992.
30. Kamb A, Gruis NA, Weaver-Feldhaus J, et al: A cell cycle regulator potentially involved in genesis of many tumor types. Science 264:436-440, 1994.
31. Ink4 mutations. N Eng J Med 333:970-974, 1995.
32. Whelan AJ, Bartsch D, Goodfellow PJ: Brief report: a familial syndrome of pancreatic cancer and melanoma with a mutation in the CDKN2 tumor-suppressor gene. N Eng J Med 333:975-977, 1995.
33. Xerri L, Grob JJ, Battyani Z, et al: NM23 expression in metastasis of malignant melanoma is a predictive prognostic parameter correlated with survival. Br J Cancer 70:1224-1228, 1994.
34. Ball NJ, Yohn JJ, Morelli JG, et al: RAS mutations in human melanoma: a marker of malignant progression. J Invest Dermatol 102:285-290, 1994.
35. Heaton KM, Rippon MB. el-Naggar A. et al: Prognostic implications of DNA index in patients with stage III cutaneous melanoma. Am J Surg 166:648-653, 1993.
36. Albino AP, Davis BM. Nanus DM: Induction of growth factor RNA expression in human malignant melanoma; markers of transformation. Cancer Res 51:4815-4820, 1991.
37. Becker D, Meier CB, Herlyn M: Proliferation of human malignant melanomas is inhibited by antisense olgodeoxynucleotides targeted against basic fibreoblast growth factor. EMBO J 8:3685-3691, 1989.
38. Dotto GP, Moellmann G, Ghosh S, et al: Transformation of murine melanocytes by basic fibroblast growth factor cDNA and oncogenes and selective suppression of the transformed phenotype in a reconstituted cutaneous environment. J Cell Biol 109[6 Pt 1]:3115-3128, 1989.
39. Yamanishi DT, Graham MJ, Florkiewicz RZ, et al: Differences in basic fibroblast growth factor RNA and protein levels in human primary melanocytes and metastatic melanoma cells. Cancer Res 52:5024-5029, 1992.
40. Merimsky O, Shoenfeld Y, Chaitchik S, et al: Antigens and antibodies in malignant melanoma. Tumor Biol, 15:188-202, 1994.
41. Hoon DS, Wang Y, Dale PS, et al: Detection of occult melanoma cells in blood with a multiple-marker polymerase chain reaction assay. J Clin Oncol, 13:2109-2116, 1995.
42. Becker JC, Brabletz T, Czemy C, et al: Tumor escape mechanisms from immunosurveillance: induction of unresponsiveness in a specific MHC-restricted CD4: human T cell clone by the autologous MHC class II: melanoma. Int Immunol 5:1501-1508, 1993.
43. Houghton AN: Cancer antigens: immune recognition of self and altered self. J Exp Med 180:1-4, 1994.
44. Ferrone S, Marincola FM: Loss of HLA class antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol Today. 16:487-494, 1995.
45. Mitchell MS, Harel W. Groshen S: Association of HLA phenotype with response to active specific immunotherapy of melanoma. J Clin Oncol, 10:1158-1164, 1992.
46. Topalian SL, Rivoltini L, Mancini M, et al: Human CD4+ T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene. Proc Natl Acad Sci USA 91:9461-9465, 1994.
47. Ruiter DJ, Mattijssen V, Broecker EB, Ferrone S: MHC antigens in human melanomas. Semin Cancer Biol 2:35-45, 1991.
48. Lee JE, Reveille JD, Ross MI, Platsoucas CD: HLA-DQB1 *0301 association with increased cutaneous melanoma risk. Int J Cancer 59:510-513, 1994.
49. Lee JE, Loflin PT, Laud PR, et al: The human leukocyte antigen TAP2 gene defines the centromeric limit of melanoma susceptibility on chromosome 6p. Tissue Antigens 47:117-121, 1996.
50. Lee JE, Lu M, Mansfield PF, et al: Malignant Melanoma: Relationship of the human leukocyte antigen class II gene DQBl *0301 to disease recurrence in American Joint Committee on Cancer Stage 1 or II. Cancer 78:758-763, 1996.